Düsseldorf (ots) –
- Turnover +11.6 %, Adjusted EBITDA +13.1 %
- Organic development compared to pro -forma numbers Q1 2024: sales -6.5 %, Adjusted EBITDA -9.3 %
- Q1 significantly influenced by sales of sales in the syringe business
- Forecast 2025 confirmed: Organic sales growth of 3-5 % and Adjusted Ebitda margin of 22 %
Gerresheimer, innovative system and solution provider as well as a global partner for the pharmaceutical, biotech and cosmetics industry, recorded a leap and result leap through the first inclusion of the Bormioli Pharma, which was acquired in 2024. Sales in the 1st quarter of 2025 rose by 11.6 % to EUR 520.1 million (Q1 2024: 466.1 million euros), Adjusted Ebitda rose by 13.1 % to EUR 91.5 million (Q1 2024: 80.9 million euros). The organic development compared to the Pro-Forma numbers of the previous year’s quarter reflects a shift in sales in the syringe business and a steamed demand from Milded Glass, especially in the area of cosmetics. Organic sales in the 1st quarter of 2025 compared to the 1st quarter of 2024 decreased by 9.3 %. The Adjusted Ebitda margin was 17.6 % (Q1 2024: 17.4 %). Based on existing contracts with further production runs in the course of the year and the good order input from the 1st quarter of 2025, Gerresheimer confirms its forecast for the 2025 financial year. The Adjusted Ebitda margin should improve to around 22 %.
“With the acquisition of Bormioli Pharma, we have significantly strengthened our market position and achieved a completely new sales and result dimension,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “We will continue our profitable growth again from the second quarter at the organic level. This will contribute to this. Among other things, injection sales, which we now expect in the second and third quarter. Overall, our High Value Solutions for biopharmaceuticals and the start of new production lines from our growth projects will be important growth drivers in 2025.”
Plastics & Devices: persistently high demand, but postponement of sales
The Plastics & Devices division generated sales of EUR 294.5 million in the 1st quarter of 2025 (Q1 2024: 258.4 million euros). Absolutely, sales due to the inclusion of Bormioli Pharma increased by 14.0 %. The sales decreased organically by 3.3 % compared to the Pro-forma figures of the 1st quarter of 2024. The main cause was the shift of sales in the syringe business into the 2nd and 3rd quarter of 2025.
Adjusted EBITDA grew by 7.0 % and reached EUR 63.4 million (Q1 2024: 59.3 million euros). Organically, the Adjusted EBITDA was 11.4 % below the Pro-forma numbers of the previous year’s quarter. In the Adjusted Ebitda margin of 21.5 % (Q1 2024: 22.9 %), the temporarily changed product mix is reflected by shifting the injection sales. The good order intake in the 1st quarter shows the continued high demand for drug delivery systems such as injections, inhalators and pens as well as containment solutions made of plastic.
Primary Packaging Glass: Margen expansion by changing the product mix
The Primary Packaging Glass division achieved sales of EUR 227.1 million in the 1st quarter of 2025 (Q1 2024: 208.4 million euros). Absolutely sales increased by 9.0 %due to the inclusion of Bormioli Pharma. The sales decreased organically by 10.2 % compared to the Pro-forma figures of the 1st quarter of 2024. The background was a subdued demand from Moulded Glass in the area of cosmetics.
Adjusted EBITDA rose by 15.4 % to 40.2 million euros (Q1 2024: 34.8 million euros). Organically, the Adjusted EBITDA was 5.8 % below the Pro-forma numbers of the previous year’s quarter. Adjusted Ebitda margin rose to 17.7 % (Q1 2024: 16.7 %). The margin expansion is due to a higher proportion of High Value Solutions.
Confirmation of the forecast
On the basis of existing contracts with further production runs in the course of the year and the good order input from the 1st quarter of 2025, Gerresheimer confirms its forecast for the 2025 financial year. In the next few years, Gerresheimer also expects the strong growth in systems and solutions for biopharmaceuticals, the successful implementation of the growth projects and the extended portfolio of High Value Solutions profitable growth.
Forecast for the 2025 financial year
- Sales growth: 3 – 5 % (organic)
- Adjusted Ebitda margin: around 22 % (organic)
- Adjusted EPS growth: high single-digit percentage range (currency-adjusted)
Medium -term forecast (organic)
- Sales growth: 8 – 10 % CAGR
- Adjusted EBITDA-Marge: 23 – 25 %
- Adjusted EPS-Wachstum: >= 10 % CAGR
The quarterly notification for the 1st quarter of 2025 is available on the Gerresheim website:
https://www.gerresheimer.com/unternehmen/investor-relations/berichte